February 20, 2018 1:39 PM ET

Life Sciences Tools and Services

Company Overview of Camargo Pharmaceutical Services, LLC

Company Overview

Camargo Pharmaceutical Services, LLC provides drug development services to clients worldwide. It offers pre-phase I services, such as due diligence, feasibility assessment, pre-clinical, clinical program development, protocol design and implementation, and pre-IND and IND preparation and submission; chemistry, manufacturing, and control services, including API, formulation, packaging, CMO oversight, and medical writing; and phase I services, such as protocol design and implementation, CRO, CTM, data management, pharmacokinetics, medical writing, and biologics. The company provides phases II-III services, including protocol review, CRO, proof-of-concept, data management, and medical writing; ...

9825 Kenwood Road

Suite 203

Cincinnati, OH 45242-6521

United States

Founded in 2003





Key Executives for Camargo Pharmaceutical Services, LLC

Chief Executive Officer and President
Chief Scientific Officer and Executive Vice President
Chief Financial Officer
Chief Operating Officer
Chief Medical Officer
Compensation as of Fiscal Year 2017.

Camargo Pharmaceutical Services, LLC Key Developments

Camargo Pharmaceutical Services, LLC Presents at BIO One-on-One Partnering™, Jan-07-2018

Camargo Pharmaceutical Services, LLC Presents at BIO One-on-One Partnering™, Jan-07-2018 . Venue: San Francisco, California, United States.

Camargo Pharmaceutical Services, LLC Presents at 2017 BIO Investor Forum, Oct-17-2017

Camargo Pharmaceutical Services, LLC Presents at 2017 BIO Investor Forum, Oct-17-2017 . Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.

Lumosa Therapeutics Co Ltd Enters into Agreement with Camargo Pharmaceutical Services LLC for the Development of Naldebain in the US

Lumosa Therapeutics Co Ltd. has entered into agreement with Camargo Pharmaceutical Services LLC, for the development of Naldebain in the US. Naldebain's active ingredient, nalbuphine, is formulated in a depot formulation and offers lasting pain relief of opioid potency with little risk of abuse and respiratory depression. The transaction enables Lumosa and Camargo Pharma to accelerate the development of Naldebain in the US.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

December 11, 2017
Camargo Pharmaceutical Services LLC, Worldwide rights of Solifenacin DRG
Private Placement
March 16, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Camargo Pharmaceutical Services, LLC, please visit www.camargopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.